Perrigo (NYSE:PRGO) Releases FY 2026 Earnings Guidance

Perrigo (NYSE:PRGO) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 2.250-2.550 for the period, compared to the consensus earnings per share estimate of 2.110. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.

Perrigo Stock Performance

Shares of PRGO stock traded up $2.53 during trading hours on Wednesday, reaching $13.31. 5,191,670 shares of the company’s stock were exchanged, compared to its average volume of 3,196,451. Perrigo has a fifty-two week low of $9.23 and a fifty-two week high of $24.60. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. The stock has a market capitalization of $1.84 billion, a P/E ratio of -1.02, a P/E/G ratio of 1.28 and a beta of 0.51. The business has a fifty day moving average price of $10.52 and a 200-day moving average price of $11.56.

Perrigo (NYSE:PRGO) last announced its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.16. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. Perrigo’s revenue was down 3.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.06) earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Analysts predict that Perrigo will post 2.09 EPS for the current fiscal year.

Perrigo Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 28th will be paid a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 8.7%. The ex-dividend date is Friday, August 28th. Perrigo’s dividend payout ratio (DPR) is presently -8.85%.

Analysts Set New Price Targets

PRGO has been the subject of several recent research reports. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Perrigo has an average rating of “Hold” and an average price target of $19.33.

Perrigo News Roundup

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Quarterly earnings beat estimates: Perrigo reported adjusted EPS of $0.50, above the $0.31–$0.34 consensus range and ahead of the $0.06 loss reported in the year-ago period. Revenue of approximately $1.02 billion also surpassed expectations of about $1.01 billion. Perrigo Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Full-year EPS outlook is favorable: Perrigo provided FY 2026 EPS guidance of $2.25 to $2.55, above the roughly $2.11 analyst consensus. Revenue guidance of $4.0 billion to $4.2 billion is broadly consistent with expectations, suggesting management anticipates stronger performance in the second half. Perrigo Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Operational and portfolio improvements: Management cited market-share gains in U.S. store-brand over-the-counter products and key European brands. Perrigo also completed its Dermacosmetics divestiture and is reviewing its Infant Formula and Oral Care businesses, actions that could simplify the portfolio and support debt reduction.
• Neutral Sentiment: Infant Formula sales increased 23.1%, helped by contract-shipment timing and higher store-brand demand, but the benefit may not fully repeat in subsequent quarters.
• Negative Sentiment: Revenue declined year over year: Net sales fell approximately 3.1%–3.2% to $1.02 billion, while core organic sales decreased 3.5%. Perrigo also cited category softness and macroeconomic headwinds.
• Negative Sentiment: The company held approximately $3.3 billion of total debt against $400 million in cash at quarter-end, leaving leverage as an important risk despite reported profitability improvement.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in PRGO. Van ECK Associates Corp lifted its holdings in Perrigo by 99.9% during the 4th quarter. Van ECK Associates Corp now owns 83,111 shares of the company’s stock valued at $1,157,000 after purchasing an additional 41,531 shares during the last quarter. Perbak Capital Partners LLP bought a new stake in Perrigo during the third quarter worth about $907,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Perrigo by 5.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 40,013 shares of the company’s stock valued at $891,000 after acquiring an additional 2,088 shares during the last quarter. Guggenheim Capital LLC grew its position in Perrigo by 10.5% during the 4th quarter. Guggenheim Capital LLC now owns 59,109 shares of the company’s stock worth $823,000 after acquiring an additional 5,619 shares during the last quarter. Finally, American Century Companies Inc. raised its position in Perrigo by 18.5% in the 2nd quarter. American Century Companies Inc. now owns 29,816 shares of the company’s stock valued at $797,000 after purchasing an additional 4,659 shares during the last quarter. 95.91% of the stock is owned by institutional investors.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.